NICE
Cancer Drugs Fund to stay, government to announce
September 27, 2013Medical Communications, Sales and Marketing CDF, Cameron, NHS, NICE, VBP, prime minister
The UK’s prime minister is set to announce that the controversial Cancer Drugs Fund will remain in place after March …
NICE: final ‘no’ for Xalkori
September 25, 2013Sales and Marketing NICE, NSCLC, Pfizer, Xalkori
Pfizer’s worst fears have been confirmed today by NICE, which has rejected its new lung cancer drug Xalkori because of …
NICE: we need more Aubagio data
September 18, 2013Sales and Marketing Aubagio, Genzyme, MS, NICE, Sanofi
NICE queries pharma R&D costs
September 5, 2013Research and Development, Sales and Marketing Dillon, NICE, Pfizer, R&D
NICE has questioned whether pharma really spends as much as it says it does on bringing new treatments to market …
Rare disease drugs ‘need separate budget’
September 3, 2013Research and Development, Sales and Marketing NHS, NICE, rare diseases
A group of MPs in the UK are calling for a ring-fenced fund to pay for drugs for rare and …
ThromboGenics/Novartis’ Jetrea gains NICE ‘yes’
August 30, 2013Alcon, Jetrea, NICE, Novartis, ThromboGenics
‘Inequality’ for Welsh cancer patients
August 28, 2013Sales and Marketing CDF, Cancer, England, NHS, NICE, Wales
Cancer sufferers in England are four times more likely to receive newer treatments on the NHS than patients in Wales, …
Price cut not enough for Pfizer’s Xalkori
August 16, 2013Sales and Marketing NICE, Pfizer, Xalkori, lung cancer
In final draft guidance NICE has rejected Pfizer’s new lung cancer drug Xalkori because of its high cost. The Institute …
AllTrials campaign releases manifesto
August 9, 2013Medical Communications, Research and Development, Sales and Marketing Bad pharma, GSK, Goldacre, NICE, transparency
The UK clinical trial transparency initiative AllTrials has released its first detailed manifesto as it looks to ramp up pressure …
Roche breast cancer drug Perjeta rejected by NICE
August 6, 2013Sales and Marketing Cancer, NICE, Perjeta, Roche
NICE is not recommending Roche’s next generation breast cancer drug Perjeta as a treatment for a particular type of advanced …
Two non-executive directors join NICE Board
July 26, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing DoH, NICE, finbarr martin, mumford
The Department of Health has announced that two new non-executive directors will join the National Institute for Health and Care …
Benlysta once again rejected by NICE
July 25, 2013Sales and Marketing Benlysta, GSK, NHS, NICE
NICE has opened a second public consultation for GSK’s lupus drug Benlysta after the Institute has again rejected the medicine …
NICE ‘no’ for MabThera
July 23, 2013Sales and Marketing MabThera, NHS, NICE, Roche
Roche has been dealt a blow by NICE, with the health watchdog deciding that MabThera should not be used on …
